Details for New Drug Application (NDA): 206217
✉ Email this page to a colleague
The generic ingredient in ENTECAVIR is entecavir. There are eighteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the entecavir profile page.
Summary for 206217
Tradename: | ENTECAVIR |
Applicant: | Aurobindo Pharma |
Ingredient: | entecavir |
Patents: | 0 |
Pharmacology for NDA: 206217
Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
Suppliers and Packaging for NDA: 206217
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ENTECAVIR | entecavir | TABLET;ORAL | 206217 | ANDA | American Health Packaging | 60687-216 | 60687-216-25 | 30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-216-25) / 1 TABLET in 1 BLISTER PACK (60687-216-95) |
ENTECAVIR | entecavir | TABLET;ORAL | 206217 | ANDA | Aurobindo Pharma Limited | 65862-841 | 65862-841-30 | 1 BOTTLE in 1 CARTON (65862-841-30) / 30 TABLET in 1 BOTTLE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 0.5MG | ||||
Approval Date: | Aug 26, 2015 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 1MG | ||||
Approval Date: | Aug 26, 2015 | TE: | AB | RLD: | No |
Complete Access Available with Subscription